Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA:603392)
China · Delayed Price · Currency is CNY 39.84
+0.54 (1.37%)
May 6, 2026, 3:00 PM CST
SHA:603392 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,888 | 1,766 | 2,215 | 5,493 | 11,167 | 5,702 |
Other Revenue | 53.35 | 53.35 | 30.31 | 17.3 | 18.52 | 48.34 |
| 1,942 | 1,819 | 2,245 | 5,511 | 11,185 | 5,750 | |
Revenue Growth (YoY) | 2.54% | -18.99% | -59.25% | -50.73% | 94.51% | 144.25% |
Cost of Revenue | 1,151 | 1,127 | 866.34 | 1,084 | 1,198 | 850.67 |
Gross Profit | 790.77 | 691.8 | 1,379 | 4,427 | 9,987 | 4,900 |
Selling, General & Admin | 880.05 | 836.46 | 790.16 | 1,878 | 3,490 | 1,874 |
Research & Development | 521.52 | 550.36 | 874.57 | 1,177 | 1,091 | 677.42 |
Other Operating Expenses | 36.66 | 12.46 | 14.67 | 31.57 | 51.28 | 26.71 |
Operating Expenses | 1,491 | 1,422 | 1,691 | 3,063 | 4,723 | 2,662 |
Operating Income | -700.18 | -730.56 | -312.22 | 1,364 | 5,265 | 2,238 |
Interest Expense | -6.01 | -6.46 | -8.32 | -6.86 | -7.67 | -5.69 |
Interest & Investment Income | 93.29 | 99.11 | 169.09 | 186.88 | 78.26 | 21 |
Currency Exchange Gain (Loss) | -14.47 | -14.47 | 7.42 | 13.01 | 27.89 | -8.75 |
Other Non Operating Income (Expenses) | -16.16 | -4.77 | -8.92 | -1.87 | -1 | 0.05 |
EBT Excluding Unusual Items | -643.53 | -657.15 | -152.95 | 1,555 | 5,362 | 2,244 |
Gain (Loss) on Sale of Investments | 45.11 | 48.3 | 36.71 | 24.66 | 9.98 | 0.03 |
Gain (Loss) on Sale of Assets | 58.04 | 58.04 | 7.39 | -1.08 | -2.74 | -0.97 |
Asset Writedown | -11.26 | - | - | -259.15 | - | - |
Other Unusual Items | 68.79 | 69.93 | 176.33 | 73.7 | 213.42 | 80.85 |
Pretax Income | -482.86 | -480.89 | 67.48 | 1,393 | 5,583 | 2,324 |
Income Tax Expense | -78.15 | -66.92 | -41.61 | 146.89 | 719.39 | 244.93 |
Earnings From Continuing Operations | -404.71 | -413.96 | 109.09 | 1,247 | 4,863 | 2,079 |
Minority Interest in Earnings | 16.23 | 15.7 | -2.86 | 1.18 | -127.51 | -57.75 |
Net Income | -388.47 | -398.27 | 106.24 | 1,248 | 4,736 | 2,021 |
Net Income to Common | -388.47 | -398.27 | 106.24 | 1,248 | 4,736 | 2,021 |
Net Income Growth | - | - | -91.48% | -73.65% | 134.28% | 198.59% |
Shares Outstanding (Basic) | 1,313 | 1,285 | 1,328 | 1,260 | 1,250 | 1,230 |
Shares Outstanding (Diluted) | 1,313 | 1,285 | 1,328 | 1,260 | 1,250 | 1,230 |
Shares Change (YoY) | -2.27% | -3.25% | 5.37% | 0.86% | 1.55% | 2.96% |
EPS (Basic) | -0.30 | -0.31 | 0.08 | 0.99 | 3.79 | 1.64 |
EPS (Diluted) | -0.30 | -0.31 | 0.08 | 0.99 | 3.79 | 1.64 |
EPS Growth | - | - | -91.92% | -73.88% | 130.69% | 190.01% |
Free Cash Flow | -806.4 | -715.41 | -532.27 | 378.15 | 3,203 | 634.16 |
Free Cash Flow Per Share | -0.61 | -0.56 | -0.40 | 0.30 | 2.56 | 0.52 |
Dividend Per Share | - | - | - | 0.320 | 0.714 | 0.099 |
Dividend Growth | - | - | - | -55.20% | 624.44% | 12.04% |
Gross Margin | 40.73% | 38.03% | 61.42% | 80.34% | 89.29% | 85.21% |
Operating Margin | -36.06% | -40.16% | -13.91% | 24.75% | 47.07% | 38.91% |
Profit Margin | -20.01% | -21.89% | 4.73% | 22.64% | 42.34% | 35.15% |
Free Cash Flow Margin | -41.53% | -39.33% | -23.71% | 6.86% | 28.63% | 11.03% |
EBITDA | -410.31 | -446.52 | -51.51 | 1,579 | 5,401 | 2,334 |
EBITDA Margin | -21.13% | -24.55% | -2.29% | 28.66% | 48.28% | 40.59% |
D&A For EBITDA | 289.87 | 284.04 | 260.71 | 215.29 | 136.17 | 96.2 |
EBIT | -700.18 | -730.56 | -312.22 | 1,364 | 5,265 | 2,238 |
EBIT Margin | -36.06% | -40.16% | -13.91% | 24.75% | 47.07% | 38.91% |
Effective Tax Rate | - | - | - | 10.54% | 12.89% | 10.54% |
Revenue as Reported | 1,942 | 1,819 | 2,245 | 5,511 | 11,185 | 5,750 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.